VIVORYON THERAPEUTICS
Vivoryon Therapeutics is a Germany based biopharmaceutical company engaged in the activities of research and development, preclinical and clinical trials. It is focused on the development of therapeutic products for the treatment of Alzheimer's disease and cancer. The company's pipeline products includes PQ912, PQ1565 and PQ-family.
VIVORYON THERAPEUTICS
Industry:
Biopharma Biotechnology Health Care Therapeutics
Founded:
1997-01-01
Address:
Halle An Der Saale, Sachsen-Anhalt, Germany
Country:
Germany
Website Url:
http://www.vivoryon.com
Total Employee:
101+
Status:
Active
Total Funding:
188.92 M USD
Technology used in webpage:
SPF LetsEncrypt SSL By Default Font Awesome Apache DMARC All-Inkl All-Inkl DNS Envia TEL
Similar Organizations
AlveoGene
AlveoGene is an innovative company focused on transforming rare respiratory disease outcomes using inhaled gene therapy.
AZTherapies
AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Cellestia
Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression.
Akari Therapeutics
Akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics.
Cytokinetics
Cytokinetics is a biopharmaceutical company developing therapies for debilitating diseases.
Homology Medicines
Homology Medicines is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases.
Inovio Pharmaceuticals
Inovio is a biotech company focusing on bringing to market DNA medicines for diseases associated with HPV, cancer, and infectious diseases.
Kamada
Kamada is a biopharmaceutical company engaged in developing, producing and marketing of specialty life-saving therapeutics, using a unique
Krystal Biotech
Krystal Biotech provide significant clinical benefit for patients suffering from rare debilitating disorders..
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2007-06-25 | Ingenium Pharmaceuticals AG | Ingenium Pharmaceuticals AG acquired by Vivoryon Therapeutics | N/A |
Investors List
Claus Christiansen
Claus Christiansen investment in Post-IPO Equity - Vivoryon Therapeutics
Dawn Biopharma
Dawn Biopharma investment in Post-IPO Equity - Vivoryon Therapeutics
Claus Christiansen
Claus Christiansen investment in Post-IPO Equity - Vivoryon Therapeutics
Biogen
Biogen investment in Venture Round - Vivoryon Therapeutics
HBM Healthcare Investments
HBM Healthcare Investments investment in Venture Round - Vivoryon Therapeutics
EQT Life Sciences
EQT Life Sciences investment in Venture Round - Vivoryon Therapeutics
TVM Capital
TVM Capital investment in Venture Round - Vivoryon Therapeutics
Andera Partners
Andera Partners investment in Venture Round - Vivoryon Therapeutics
BB Biotech Ventures
BB Biotech Ventures investment in Venture Round - Vivoryon Therapeutics
IBG Beteiligungsgesellschaft Sachsen-Anhalt
IBG Beteiligungsgesellschaft Sachsen-Anhalt investment in Venture Round - Vivoryon Therapeutics
Official Site Inspections
http://www.vivoryon.com Semrush global rank: 3.41 M Semrush visits lastest month: 4.04 K
- Host name: dd53506.kasserver.com
- IP address: 85.13.129.136
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "Vivoryon Therapeutics"
About Us - Vivoryon
Prior to joining Vivoryon, Anne Doering was Director of Investor Relations at BioNTech and Director of Group Strategy at Merck KGaA, where she contributed to the strategic direction of …See details»
Vivoryon Org Chart + Executive Team - The Official Board
Organizational Chart of Vivoryon. Vivoryon Org Chart www.vivoryon.com +49 345 555 9900; Add an executive. Vivoryon News . Anything missing? We search for you. Print or download . CEO …See details»
Vivoryon Therapeutics - Crunchbase Company Profile & Funding
Vivoryon Therapeutics is a Germany based biopharmaceutical company engaged in the activities of research and development, preclinical and clinical trials. It is focused on the development of …See details»
Annual Report 2023 - Vivoryon
Vivoryon Therapeutics N.V. is a Dutch public company with limited liability (‘Naamloze Vennootschap’) that has its statutory seat in Amsterdam, the Netherlands and branch offices …See details»
Vivoryon Therapeutics NV (Vivoryon Therapeutics NV) - 药物管线_ …
May 7, 2025 Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress on December 10, 2024 Halle (Saale) / Munich, Germany, December 04, 2024 - …See details»
Vivoryon Therapeutics N.V. | LinkedIn
Vivoryon is focused on developing innovative small molecule-based medicines. Driven by our passion for ground-breaking science and innovation, we strive to change the lives of patients …See details»
Vivoryon Therapeutics N.V. Expands Intellectual Property Portfolio …
1 hour ago Halle (Saale) / Munich, Germany, May 27, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on …See details»
Vivoryon Therapeutics - VentureRadar
At Vivoryon, we are passionate about creating small molecule medicines to improve the lives of all those who are affected by severe diseases. We build on our in-depth expertise in …See details»
Vivoryon Therapeutics NV - Drug pipelines, Patents, Clinical trials ...
May 7, 2025 Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data fromVIVA-MIND Strongly Supporting Varoglutamstat’s Potential toImprove Kidney Function VIVA-MIND Phase …See details»
Our Approach - Vivoryon
At Vivoryon, we are passionate about creating small molecule medicines to improve the lives of all those who are affected by severe diseases. We build on our in-depth expertise in …See details»
Vivoryon Therapeutics - EQT Group
Vivoryon Therapeutics. Do You Want to Know More? We are eager to explore how we can achieve great things together. Contact us. A Purpose-Driven Global Investment Organization. …See details»
Vivoryon Therapeutics - Craft
Oct 29, 2024 Vivoryon Therapeutics (previously known as Probiodrug) is a precision intervention company specializing in discovering and developing therapies for patients suffering from age …See details»
Vivoryon Therapeutics
Vivoryon Therapeutics N.V. is a biotechnology company developing innovative, orally available small molecule drugs for various indications such as Alzheimer’s disease, inflammatory and …See details»
Vivoryon Therapeutics - Funding, Financials, Valuation & Investors
Vivoryon Therapeutics is registered under the ticker AMS:VVY . Vivoryon Therapeutics is funded by 13 investors. Yorkville Advisors and Claus Christiansen are the most recent investors. …See details»
Vivoryon Therapeutics N.V. Information - RocketReach
Vivoryon is focused on developing innovative small molecule-based medicines. Driven by our passion for ground-breaking science and innovation, we strive to change the lives of patients …See details»
Vivoryon Therapeutics - Overview, News & Similar companies
Dec 3, 2023 Who is Vivoryon Therapeutics. With 20+ years of unmatched understanding in identifying post-translational modifying enzymes that play critical roles in disease initiation and …See details»
Presentations & Webcasts - Vivoryon
Sep 12, 2024 April 24, 2024 Presentation Full Year Results 2023. December 06, 2023 Presentation Third Quarter Results 2023. November 14, 2023 Jefferies London Healthcare …See details»
Vivoryon Therapeutics 2025 Company Profile: Stock Performance ...
Vivoryon Therapeutics NV is a Germany-based biopharmaceutical company engaged in the activities of research and development, preclinical and clinical trials. It is focused on the …See details»
Vivoryon Therapeutics N.V. Expands Intellectual Property
1 hour ago Vivoryon Therapeutics N.V. to Hold its 2025 Annual General Meetingon June 24, 2025 Halle (Saale) / Munich, Germany, May 13, 2025 - Vivoryon Therapeutics N.V. (Euronext …See details»
Investors & News - Vivoryon
1 day ago Vivoryon Therapeutics N.V. to Hold its 2025 Annual General Meetingon June 24, 2025 Vivoryon Therapeutics N.V. Reports Full Year 2024 Financial Results and Provides …See details»